Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2a dose-finding and dose-confirmation study of Nerofe in high-risk myelodysplastic syndrome or acute myeloid leukemia
MOH_2018-05-01_002319Phase 2Completed
- Sponsor
- חברת מפתח מערכת החיסון
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibuprofen in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by חברת מפתח מערכת החיסון. Primary endpoints: Safety, Efficacy and 1 more. Started Mar 2018; status: completed.
02
Drugs
ibuprofen
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2018-05-01_002319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-01_002319.